You can buy or sell CytRx and other stocks, options, ETFs, and crypto commission-free!
CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It focuses on discovering, developing, and commercializing new therapeutics to treat patients with cancer; including aldoxorubicin, a modified version of the widely-used chemotherapeutic agent, doxorubicin. Read More The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Los Angeles, California
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMar 12
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding Cytotoxic Treatment LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Dev...
PR NewswireMar 5
Biotech Companies Intensify Research Into New Therapies to Combat Cancer
NEW YORK, March 5, 2019 /PRNewswire/ -- Cancer ranks among one of the top causes of death globally and data show that the number is still expected to increase.
-$0.07 per share
Expected Mar 28, Pre-Market